Epidermolysis Bullosa

Epidermolysis Bullosa

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Epidermolysis Bullosa is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • EB

Disorder Subdivisions

  • epidermolysis bullosa simplex
  • junctional epidermolysis bullosa
  • dystrophic epidermolysis bullosa
  • Kindler syndrome

General Discussion

Epidermolysis bullosa (EB) is a genetic skin disorder characterized clinically by blister formation from mechanical trauma. There are four main types with additional sub-types identified. There is a spectrum of severity, and within each type, one may be either mildly or severely affected. EB ranges from being a minor inconvenience requiring modification of some activities, to being completely disabling and, in some cases, fatal.



Friction causes blister formation. Blisters can form anywhere on the surface of the skin, within the oral cavity and in more severe forms may also involve the external surface of the eye, as well as the respiratory, gastrointestinal and genitourinary tracts. In some forms of the disease, disfiguring scars and disabling musculoskeletal deformities occur.



Currently, there is no cure for EB. Supportive care includes daily wound care, bandaging, and pain management as needed.

Symptoms

Epidermolysis bullosa is divided into four subdivisions, and each subdivision has subtypes.



Epidermolysis bullosa simplex (EBS) is usually dominantly inherited, and involves disorders of the genes for Keratins 5 and 14 and plectin. Recently, several suprabasal types of EBS have been described as well. Blistering occurs within the uppermost layer of the skin, the epidermis. EBS may be localized to the hands and feet or there may be a generalized distribution, with relatively mild internal involvement. Those with EBS may have thickened calluses on the palms and soles, oral blistering during infancy and rough, thickened fingernails/toenails. EBS does not usually scar. There are rare recessive forms. EBS with plectin mutations may be associated with muscular dystrophy.



Junctional epidermolysis bullosa (JEB), is recessively inherited, and involves mutations in the genes for several components of the junction between the epidermis and dermis such as Laminin 332 (previously known as Laminin 5), plectin, and a6b4integrin. There are two major subtypes, Herlitz JEB and JEB- other (includes non-Herlitz JEB, and JEB with pyloric atresia and several other subtypes). Junctional Herlitz EB is due to mutations in any of the three Laminin 332 chains and can be a very severe form of EB. Death often occurs during infancy due to overwhelming infection (sepsis), malnutrition, dehydration, electrolyte imbalance or obstructive airway complications. There is a wide spectrum of JEB- O. Oral cavity involvement and irregular pitting of the surfaces of the teeth is common in all subtypes. Infants presenting with pyloric atresia will have trouble with feeding and abdominal distension as neonates and present as surgical emergencies in the newborn period.



Dystrophic epidermolysis bullosa (DEB) can be either dominantly or recessively inherited, and involves defects in Type VII collagen. Blisters occur within the lower layer of the skin, the dermis. There are two major subtypes, dominant DEB (DDEB) and recessive DEB (RDEB).



Dominant dystrophic EB (DDEB): DDEB is usually mild. Blistering may be localized to the hands, feet, elbows and knees or it may be generalized. Common findings include scarring, milia (tiny white bumps), mucous membrane involvement, and abnormal or absent nails. Some family members may only have nail dystrophy.



Recessive dystrophic EB (RDEB): RDEB is typically more generalized and severe than DDEB. In addition to scarring, milia, mucous membrane involvement and nail dystrophy, common manifestations include malnutrition, anemia, esophageal strictures, growth retardation, webbing or fusion of the fingers and toes causing mitten deformity (pseudosyndactyly) with loss of function, development of contractures, malformation of teeth, microstomia and corneal abrasions. Severe generalized RDEB (formerly Hallopeau-Siemens RDEB) tends to be the most severe form.



Kindler syndrome is very rare and involves all layers of the skin with extreme fragility.

Causes

Inherited epidermolysis bullosa is the focus of this report. The inherited forms follow either autosomal dominant or autosomal recessive inheritance. There is also a rare acquired autoimmune disorder called epidermolysis bullosa aquisita. A mutation in any of at least 18 genes encoding the proteins in the epidermis, basement membrane or dermis causes poor integrity of the skin leading to fragility.



Recessive genetic disorders occur when an individual inherits two copies of an abnormal gene for the same trait, one from each parent. If an individual receives one normal gene and one gene for the disease, the person will be a carrier for the disease but usually will not show symptoms. The risk for two carrier parents to both pass the defective gene and have an affected child is 25% with each pregnancy. The risk to have a child who is a carrier like the parents is 50% with each pregnancy. The chance for a child to receive normal genes from both parents and be genetically normal for that particular trait is 25%. The risk is the same for males and females.



All individuals carry at least 4-5 abnormal genes. Parents who are close relatives (consanguineous) have a higher chance than unrelated parents to both carry the same abnormal gene, which increases the risk to have children with a recessive genetic disorder.



Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary to cause a particular disease. The abnormal gene can be inherited from either parent or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy. The risk is the same for males and females.

Affected Populations

Some type of EB occurs in an estimated 1 out of every 50,000 live births. The disorder occurs in every racial and ethnic group throughout the world and affects both sexes equally.

Standard Therapies

Diagnosis

Clinical diagnosis of the type of EB based on presentation in the neonatal period should be avoided as all types of EB may look alike in this age group. When EB is suspected, a skin biopsy should be obtained and sent to an appropriate laboratory to confirm the diagnosis with transmission electron microscopy (TEM) and/or immunofluorescent antibody/antigen mapping. Molecular genetic testing for mutations in most of the genes known to be associated with the various types of EB is clinically available.



Treatment

By definition, inherited EB is a genetically transmitted disorder characterized by marked fragility of the skin. Any trauma, no matter how minimal it may seem, is likely to cause the skin of an EB child or adult to tear or blister. The following are recommended ways to avoid or minimize this problem:



1. Reducing friction: Extreme care should be employed in handling the skin of any patient with EB.



2. Non-adhesive bandages and dressings: Adhesive or semi-adhesive dressings, bandages, Band-aids, or tape should not be used on the surface of the skin. Instead, wounds should be covered with an appropriate non-adhesive dressing and then further wrapped loosely with rolled gauze. This can be secured by using a tubular dressing retainer.



3. Keeping the skin cool: Nothing hot should ever be applied to the skin of a patient with EB. In particular, bath water should be no warmer than body temperature. Patients should avoid prolonged exposure to ambient heat and humidity. If possible, air conditioned environments should be sought whenever possible.



4. Managing blisters: Because blisters in EB are not self-limiting, and can fill with fluid and grow quite large, they need to be drained.



5. Clothing: In younger children, diapers may require additional padding at the legs and waist. Whenever possible, loose-fitting garments should be worn. If blisters develop from the seams of clothing, garments may be worn inside-out and tags, cuffs and necklines may be removed. Loosely-fitted, padded shoes are generally better tolerated.



6. Nutritional deficiencies: Many children with EB become anemic due to a chronic loss of blood through wounds, poor nutritional intake, poor absorption of iron and bone marrow suppression from chronic inflammation. It is important to work with a nutritionist experienced in the care of special needs patients. Treatment for iron deficiency anemia is often necessary. Other patients have selenium and carnitine or vitamin D deficiencies which may predispose them to cardiomyopathy and osteoporosis. Many patients develop failure to thrive and require feeding gastrostomies.



7. Monitoring for cancer: Squamous cell carcinoma is the leading cause of death in EB usually occurring after the 2nd decade of life. Patients with RDEB and JEB are at increased risk of developing skin cancers during their lifetimes. It is very important that all EB patients have at least yearly examination of all skin areas.

Investigational Therapies

Stem cell transplant therapy trials for recessive dystrophic epidermolysis bullosa are being conducted at at least two institutions. For further information contact the following :



University of Minnesota Center for Translational Medicine Tim Krepski, RN 612-273-2800 Toll-free: 1-888-601-0787

Cincinnati Children's Hospital

Epidermolysis Bullosa Center

Anne W. Lucky, MD or Richard G. Azizkhan, MD

Co-directors

513 636-2009



(Severe Junctional EB) Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office: Tollfree: (800) 411-1222 TTY: (866) 411-1010 Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact: www.centerwatch.com



For information about clinical trials conducted in Europe, contact:

https://www.clinicaltrialsregister.eu/

References

TEXT BOOKS

Fine JD, Hintner H., eds. Life with Epidermolysis Bullosa (EB): Etiology, Diagnosis, Multidisciplinary Care and Therapy, New York: Springer Wien; 2009.

Fine JD, Bauer E, McGuire J , Moshell A, eds.Epidermolysis Bullosa: Clinical, Epidemiologic, and Laboratory Advances and the Findings of the National Epidermolysis Bullosa Registry 1st edition The Johns Hopkins University Press; 1999.



Weston WL, Lane AT, Morelli JG, eds. Color Textbook of Pediatric Dermatology, 4th Edition Mosby/Elsevier, 2007: 348-354.



REVIEW ARTICLES



Murrell DF (ed.) (2010): Epidermolysis Bullosa: Part I – Pathogenesis and Clinical Features. Dermatologic Clinics, Vol 28/1. Philadelphia: W.B. Saunders Elsevier.



Murrell DF (ed.) (2010): Epidermolysis Bullosa: Part II – Diagnosis and Management. Dermatologic Clinics, Vol 28/2. Philadelphia: W.B. Saunders Elsevier.



Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues.

J Am Acad Dermatol. 2009 Sep;61(3):367-84.



Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol. 2009 Sep;61(3):387-402.



Pfendne EG, Bruckner A, Conget P, Mellerio J, Palisson F, Lucky AW. Basic science of epidermolysis bullosa and diagnostic and molecular characterization: Proceedings of the IInd International Symposium on Epidermolysis Bullosa. Santiago, Chile, 2005 International Journal of Dermatology. 2007; 46(8):781-794.



Azizkhan RG, Denyer JE, Mellerio JE, González R, Bacigalupo M, Kantor A, Passalacqua G, Palisson F, Lucky AW. Surgical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005. International Journal of Dermatology. 2007:46(8): 801-808.



Mellerio JE, Weiner M, Denyer JE, Pillay EI, Lucky AW, Bruckner A, Palisson F. Medical management of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005 International Journal of Dermatology 2007;46(8): 795- 800.



Lucky AW, Pfendner E, Pillay E, Paskel J, Weiner M, Palisson F. Psychosocial aspects of epidermolysis bullosa: Proceedings of the IInd International Symposium on Epidermolysis Bullosa, Santiago, Chile, 2005 International Journal of Dermatology. 2007;46(8): 809-814.



INTERNET

Debra International. Caring for Someone with EB. Available at: http://www.debra-international.org/patients/caring-for-someone-with-eb.html Accessed May 30, 2013.



Marinkovich MP. Epidermolysis Bullosa Updated: Aug. 10, 2012. Medscape. Available at: http://emedicine.medscape.com/article/1062939-overview Accessed May 30, 2013.



Pfendner E, Bruckner A. Epidermolysis Bullosa Simplex. Last Update Sept. 1, 2011. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org . Accessed May 30, 2013.



Pfendner E, Lucky AW. Dystrophic Epidermolysis Bullosa. Last Update Nov 4, 2010. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org . Accessed May 30, 2013.



Pfendner E, Lucky AW. Junctional Epidermolysis Bullosa. Posted: Feb 2, 2008. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org . Accessed May 30, 2013.



Pfendner E, Lucky AW. Epidermolysis Bullosa with Pyloric Atresia. Last Update: February 14, 2013. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at http://www.genetests.org Accessed May 30, 2013.

Resources

Dystrophic Epidermolysis Bullosa Research Association of America, Inc. (DEBRA)

16 East 41st Street

3rd Floor

New York, NY 10017

Tel: (212)868-1573

Fax: (212)868-9296

Tel: (866)332-7276

Email: staff@debra.org

Internet: http://www.debra.org



Oley Foundation

214 Hun Memorial MC-28

Albany Medical Center

Albany, NY 12208-3478

USA

Tel: (518)262-5079

Fax: (518)262-5528

Tel: (800)776-6539

Email: dahlr@mail.amc.edu

Internet: http://www.oley.org



Coalition for Heritable Disorders of Connective Tissue (CHDCT)

4301 Connecticut Avenue, NW Suite 404

Washington, DC 20008

Tel: (202)362-9599

Fax: (202)966-8553

Tel: (800)778-7171

Email: chdct@pxe.org

Internet: http://www.chdct2.org/



DebRA

13 Wellington Business Park

Dukes Ride

Crowthorne

Berkshire, RG45 6LS

United Kingdom

Tel: 441344771961

Fax: 441344762661

Email: debra@debra.org.uk

Internet: http://www.debra.org.uk



EB Medical Research Foundation

2757 Anchor Ave

Los Angeles, CA 90064

Tel: (310)854-0957

Email: a.pett@bep-la.com

Internet: http://www.ebkids.org



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



Epidermolysis Bullosa Action Network

16613 Milan De Avila

Tampa, FL 33613

Tel: (813)325-1955

Email: silvia@ebanusa.org

Internet: http://www.ebanusa.org



Australasian Blistering Diseases Foundation

St. George Hospital,

Department of Dermatology

Gray Street

Kogarah

Sydney, NSW 2217

Australia

Tel: 0291132088

Fax: 0291132886

Email: info@blisters.org.au

Internet: http://www.blisters.org.au/BDHome.html



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.